LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$74.22 USD
+7.45 (11.16%)
Updated May 3, 2024 04:00 PM ET
After-Market: $74.43 +0.21 (0.28%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LMAT 74.22 +7.45(11.16%)
Will LMAT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LMAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LMAT
LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Top Estimates
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
LMAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain Medtronic (MDT) Stock for Now
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
Other News for LMAT
Buy Rating Affirmed: LeMaitre Vascular’s Strong Performance and Upward Financial Trajectory
LeMaitre price target raised by $10 at Barrington, here's why
Lake Street Sticks to Its Buy Rating for Lemaitre Vascular (LMAT)
Oppenheimer Reaffirms Their Buy Rating on Lemaitre Vascular (LMAT)
LeMaitre price target raised by $5 at JMP Securities, here's why